testalize-me-0je8ynv4mis-unsplash

Sanofi shares phase 3 trial results for Sarclisa in multiple myeloma treatment

Betsy Goodfellow | June 5, 2024 | News story | Research and Development |  Oncology, Sanofi, Sarclisa, clinical trial, multiple myeloma 

Sanofi has announced data from the IMROZ phase 3 trial which assessed Sarclisa (isatuximab) in combination with standard-of-care bortezomib, lenalidomide and dexamethasone (VRd) followed by Sarclisa-Rd, compared to VRd followed by Rd for the treatment of patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant.

The trial demonstrated that Sarclisa reduced the risk of disease progression or death by 40% compared to standard of care, indicating its ability to significantly improve progression-free survival (PFS), therefore meeting its primary endpoint.

The full results were shared in an oral presentation at the American Society of Clinical Oncology (ASCO) annual meeting as well as being published in The New England Journal of Medicine.

Advertisement

Thierry Facon MD, professor of haematology in the department of haematology at Lille University Hospital, France, member of the French Academy of Medicine and IMROZ principal investigator, commented: “The significant PFS benefit observed with Sarclisa combination therapy compared to VRd is important and encouraging for patients with NDMM. Effective frontline therapy has the potential to modify the course of the disease, which is a key outcome for transplant-ineligible patients who often face high rates of attrition in later lines of therapy. The IMROZ results demonstrate the promise of Sarclisa as a backbone to frontline therapy, which may improve long-term outcomes for this incurable disease.”

Betsy Goodfellow

Related Content

Amphista doses first patient in AML trial of protein degrader

Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an …

Tridem begins phase Ib trial of Parkinson’s disease vaccine

Tridem Bioscience has enrolled the first patients in a phase Ib clinical trial of TRB-001, …

How will biomarker-led diagnostics reshape respiratory medicine?

By Dr Louise Ryan Murphy, Chronic obstructive pulmonary disease (COPD) is typically diagnosed and assessed …

The Gateway to Local Adoption Series

Latest content